Daiichi Sankyo (OTCMKTS:DSNKY) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Daiichi Sankyo (OTCMKTS:DSNKY) from a strong sell rating to a hold rating in a research note published on Monday morning,Zacks reports.

Separately, Jefferies Financial Group cut Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has an average rating of “Hold”.

Daiichi Sankyo Price Performance

OTCMKTS DSNKY opened at $19.00 on Monday. The stock has a fifty day moving average of $17.67 and a 200-day moving average of $17.27. The stock has a market capitalization of $35.39 billion, a P/E ratio of 22.09, a price-to-earnings-growth ratio of 2.61 and a beta of -0.11. Daiichi Sankyo has a 52 week low of $14.98 and a 52 week high of $27.50. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings results on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, equities research analysts forecast that Daiichi Sankyo will post 0.97 EPS for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies.